All MHRA articles
-
News
MHRA highlights liver injury risk with combination therapy for cystic fibrosis
The MHRA has issued a drug safety update highlighting the risk of serious liver injury following treatment with a combination therapy for cystic fibrosis
-
News
MHRA issues warning on concurrent use of macrolide antibiotics in patients on hydroxychloroquine
The alert follows a review by the MHRA along with the Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines
-
News
Novavax COVID-19 vaccine approved by the MHRA
The MHRA has given conditional marketing authorisation to Nuvaxovid, a COVID-19 vaccine developed by Novavax. It is the fifth COVID jab for which the MHRA has given regulatory approval
-
News
MHRA approves first oral antiviral for COVID-19
The MHRA has found the antiviral to be safe and effective following a rigorous review of the evidence
-
News
MHRA co-publishes 10 guiding principles for developing good machine learning practices
The MHRA has collaborated with international regulators to produce 10 guiding principles for the use of artificial intelligence or machine learning in medical devices
-
News
MHRA announces consultation on regulation of medical devices
The MHRA has called for input into a consultation on how it can improve medical device regulation
-
News
Long-term topical steroid use linked to skin withdrawal symptoms
The MHRA is advising people experiencing skin withdrawal reactions after stopping topical steroids to seek advice from their healthcare professional
-
News
Pfizer and Vaxzevria COVID vaccines approved for use as boosters
MHRA approval will provide further options for the UK COVID-19 vaccination programme, should the JCVI recommend that booster doses be offered
-
News
MHRA recalls 25 batches of contaminated irbesartan
The recall alert for pharmacies and wholesalers is due to an increased risk of cancer from an impurity in the contaminated batches
-
News
MHRA’s new delivery plan aims to put patients first
Putting patients first: a new era for our agency replaces the agency’s current corporate plan and sets out its roadmap for the future